NeuroDerm Ltd.: NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations

ND0612, a continuous 24 hours/day subcutaneous (SC) infusion?of liquid levodopa/carbidopa (LD/CD), showed superior efficacy compared to oral LD/CD for the primary endpoint ("ON" time without

Related Keywords

Rehovot ,Hamerkaz ,Israel ,Germany ,Osaka ,Japan ,United States ,United Kingdom ,American ,Kostenloser Wertpapierhandel ,C Warren Olanow ,Tanabe Pharma Gmb ,Enola Chen ,Pharma Deutschland Gmb ,Mitsubishi Chemical Group ,Neuroderm Ltd ,Linkedin ,American Academy Of Neurology Annual Meeting ,Mitsubishi Tanabe Pharma Corporation ,Medicine Committee International Parkinson ,Mitsubishi Pharma Europe Ltd ,Movement Disorder Society Evidence ,Prnewswire Neuroderm Ltd ,Parkinson Foundation ,Michaelj Fox Foundation ,Unified Parkinson ,Disease Rating Scale Part ,Patient Global Impression ,Clinical Global Impression ,Derm Ltd ,About Parkinson ,Mitsubishi Chemical ,Tanabe Pharma Corporation ,Tanabe Pharma Gmbh ,Mitsubishi Pharma Deutschland Gmbh ,Mitsubishi Pharma Europe ,Mitsubishi Tanabe Pharma Cooperation ,Neural Transm ,Choice Between Advanced Therapies ,Disease Patients ,Tolerability Study ,Motor Fluctuations ,Accessed November ,American Academy ,Neurology Annual Meeting ,Has Parkinson ,Accessed March ,Rev Dis ,Warren Olanow ,Drug Insight ,Nat Rev ,Neuroderm ,Nnounces ,Ighly ,Positive ,Results ,Rom ,Pivotal ,Hase ,Groundless ,Trial ,Valuating ,D0612 ,Parkinson ,Disease ,Patients ,Motor ,Fluctuations ,